BRCA2 and cancer: Our findings may have clinical implications for the assessment of variants of unknown clinical significance (VUS) located at the NTD as defects in HR-repair of replicative lesions would not be picked up by the current methods to assess HR proficiency30,57,62 as exemplified in the case of BRCA2-C315S or BRCA2-S273L, but may nonetheless be linked to cancer predisposition given the genome instability observed in cells bearing these variants.